Tempo Pharmaceuticals Garners $8,000,000 Series B Financing
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=95c37f3a-5181-4387-a0d7-ffb8d3044d6e&Preview=1
Date 1/3/2008
Company Name Tempo Pharmaceuticals
Mailing Address 161 First Street Cambridge, MA 02142
Company Description Tempo Pharmaceuticals is a private biopharmaceutical company focused on the development of novel, nanotechnology-based therapeutics in the areas of oncology, autoimmune and inflammatory diseases. The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Millennium Pharmaceuticals, Pfizer, Pharmacia, the Massachusetts Institute of Technology, Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center.
Proceeds Purposes Proceeds from the financing will be used to accelerate the development of Tempo’s preclinical pipeline of multi-compartmental, nanoparticle-based drugs that have the potential to substantially improve the efficacy and safety of existing and new therapeutics.
M&A Terms
Venture Investor Polaris Venture Partners
Venture Investor Venrock
Venture Investor Bessemer Venture Partners
Venture Investor Alexandria Real Estate Equities, Inc.